{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:45:54Z","timestamp":1772120754112,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["20120230"],"award-info":[{"award-number":["20120230"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["NCT01785849"],"award-info":[{"award-number":["NCT01785849"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["NCT01788046"],"award-info":[{"award-number":["NCT01788046"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ekir.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T21:14:03Z","timestamp":1555362843000},"page":"987-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients"],"prefix":"10.1016","volume":"4","author":[{"given":"John","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Iles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Bushinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2019.04.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2019.04.010_bib2","first-page":"S1","article-title":"KDIGO Clinical Practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2019.04.010_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2019.04.010_bib4","first-page":"i12","article-title":"Secondary hyperparathyroidism disease stabilization following calcimimetic therapy","volume":"1","author":"Fr\u00e3zao","year":"2008","journal-title":"NDT Plus"},{"key":"10.1016\/j.ekir.2019.04.010_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2019.04.010_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5414\/CN106965","article-title":"Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity","volume":"76","author":"Frazao","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.04.010_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2265.2000.01081.x","article-title":"Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis","volume":"53","author":"Sudhaker Rao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ekir.2019.04.010_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5414\/CN108629","article-title":"Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis","volume":"85","author":"Block","year":"2016","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.04.010_bib9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.V9101845","article-title":"High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in\u00a0vitro","volume":"9","author":"Almaden","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.04.010_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/ndt\/gfs598","article-title":"Correlates of parathyroid hormone concentration in hemodialysis patients","volume":"28","author":"Li","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.04.010_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2369-13-76","article-title":"Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?","volume":"13","author":"Fr\u00e3zao","year":"2012","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.04.010_bib12","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.04.010_bib13","doi-asserted-by":"crossref","first-page":"c124","DOI":"10.1159\/000345164","article-title":"Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients","volume":"121","author":"Cooper","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2019.04.010_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ckj\/sft026","article-title":"Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism Results mainly from parathyroid hormone reduction","volume":"6","author":"Zitt","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2019.04.010_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjoto.2018.01.006","article-title":"Thirty-day readmissions following parathyroidectomy: evidence from the National Readmissions Database, 2013\u20132014","volume":"39","author":"Kravietz","year":"2018","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ekir.2019.04.010_bib16","doi-asserted-by":"crossref","first-page":"e9050","DOI":"10.1097\/MD.0000000000009050","article-title":"Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2019.04.010_bib17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pds.3845","article-title":"Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation","volume":"24","author":"Brunelli","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ekir.2019.04.010_bib18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.21037\/gs.2017.09.12","article-title":"Near total parathyroidectomy for the treatment of renal hyperparathyroidism","volume":"6","author":"Puccini","year":"2017","journal-title":"Gland Surg"},{"key":"10.1016\/j.ekir.2019.04.010_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0272-6386(03)00909-0","article-title":"Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism","volume":"42","author":"Yajima","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.04.010_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/IJNRD.S56995","article-title":"Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients","volume":"7","author":"Florescu","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919301573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919301573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:24:06Z","timestamp":1762831446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024919301573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2468024919301573"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2019.04.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736085337.793577508","asserted-by":"object"}]},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}